Cantor Fitzgerald analyst Li Watsek raised the firm’s price target on Ascendis Pharma (ASND) to $254 from $203 and keeps an Overweight rating on the shares. The firm updated its patient flow model for Yorvipath and now sees largely in-line Q3 sales of $179M vs. $177M consensus, as the Street has caught up to the initial strong launch trajectory, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Submits EMA Application for Achondroplasia Treatment
- Ascendis Pharma submits TransCon CNP marketing authorization application to EMA
- Ascendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Wedbush sees no threat to Ascendis’ Yorvipath from competitor data